Cirrhosis is an advanced stage in the development of various chronic liver diseases and is clinically classified into early and advanced cirrhosis. When a patient develops liver ascites, splenomegaly, portal hypertension, and inverted protein ratio, it may be advanced cirrhosis. It means that the liver is severely damaged and loses its normal physiological function, which makes the treatment difficult. However, due to the strong compensatory capacity of the liver, if cirrhosis can be identified early and given timely and effective treatment, most patients can still be cured or have their condition under control. Therefore, early diagnosis and early treatment of cirrhosis is the key to prevent the emergence of cirrhotic ascites. Most patients with early cirrhosis do not have any special manifestations, only some of them can have general discomfort and chronic dyspepsia symptoms, such as general weakness, easy fatigue, loss of energy, abdominal distension, constipation, diarrhea, vague pain in the liver area, obvious after exertion. In a few patients, spider nevus can be seen, and the spleen can be normal or mildly enlarged. These symptoms are often confused with existing chronic liver disease and do not attract the attention of patients. Therefore, patients with chronic liver disease and Ao-positive patients are asymptomatic for a long time, and sometimes liver function is only found to be abnormal when they are examined, or when they have symptoms, they are already in the advanced stage of cirrhosis. Therefore, patients with chronic liver disease. If there are the following conditions should be alert to the possibility of early cirrhosis. 1.Unexplained indigestion symptoms, especially loss of appetite, abdominal distension, diarrhea, etc. 2.Unspecified cause of splenomegaly. 3.Unspecified cause of gynecomastia. 4.Recurrent liver function or transaminase abnormalities. 5.Patients with recurrent chronic intestinal infections or ulcerative colitis. Those with the above symptoms should have timely liver function tests, protein ratios, serum type III precollagen peptide and related enzymatic tests, and B ultrasound to observe changes in liver and spleen size. If cirrhosis has not yet developed, chronic liver disease should be actively treated to control the progression of the disease. For example, patients with hepatitis B, hepatitis C and major and minor triplets should be actively treated with antiviral, immune adjustment and restoration of liver function. Clinical prescriptions and drugs should be flexibly selected according to different ages, genders and conditions to promote the conversion of major triplets and minor triplets as soon as possible. Patients with fatty liver should undergo medication and diet adjustment, combining treatment of fatty liver with weight loss and lipid lowering to end the evolution to cirrhosis. If cirrhosis develops, we should seek the root cause of the disease and treat it with evidence, combining improvement of liver function, immune adjustment, anti-virus and spleen reduction.